Scars
Also known as: Cicatrix, Keloid scar, Hyperplasia, Hyperplastic, Hypertrophic
Methodology & AI Transparency ⓘ
Scars Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A scar is a permanent patch of skin that grows over a wound .
- 2 Real-world patient consensus: Clinical coding for Scars uses ICD-10 L90.5 across Skin & Dermatology specialty care.
- 3 Typical cash cost range: Primary evaluation for Scars incorporates contact/systemic trigger review [Scars L90.5] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Scars: 25-Hydroxy Vitamin D in Scars (L90.5: & hs-CRP) (25(OH)D 40–65 ng/mL (L90.5)) and Affected Body Surface in Scars (L90.5: Area (BSA /).
Ask our AI Specialists anything about Scars
What Is Scars?
A scar is a permanent patch of skin that grows over a wound . It forms when your body heals itself after a cut, scrape, burn, or sore. You can also get scars from surgery that cuts through the skin, infections like chickenpox, or skin conditions like acne . Scars are often thicker, as well as pinker, redder, or shinier, than the rest of your skin. How your scar looks depends on: How big and deep your wound is Where it is How long it takes to heal Your age Your inherited tendency to scar Scars usually fade over time but never go away completely. If the way a scar looks bothers you, various treatments might minimize it.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Scars (L90.5) involves cutaneous immune skewing in Scars (L90.5: (Th2/IL-4/IL-13 in atopic). Cross-referenced with NIH MeSH (Cicatrix), progression correlates with shifts in 25-Hydroxy Vitamin D in Scars (L90.5: & hs-CRP) (25(OH)D 40–65 ng/mL (L90.5)).
Common Symptoms & Clinical Signs
- • How big and deep your wound is
- • How long it takes to heal
- • Presentation of Scars (L90.5): recurrent flares triggered in Scars (L90.5: by UV exposure,)
- • Secondary Scars clinical sign: persistent erythematous plaques, in Scars (L90.5: scaly patches, pruritic)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Scars Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L90.5 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Scars (L90.5: & hs-CRP) | 25(OH)D 40–65 ng/mL (L90.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Scars (L90.5: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L90.5) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Scars (L90.5: ALT (if systemic) | Within baseline reference limits (L90.5) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Scars
Treatment selection for Scars depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Scars)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deucravacitinib in moderate-to-severe plaque psoriasis skin flare-ups: Pooled: What a 1,683-Participant Study Found Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-08-15 • Phase III Randomized Trial | N = 1,683 | 96/100 | PMID 38451052 ↗ |
| New Insights on Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients: What a 564-Participant Study Found LEB was associated with high rates of durable absolute EASI response, even in cases of high baseline severity or suboptimal week-16 outcomes. Acta dermato-venereologica • 2026-05-21 • Phase III Randomized Trial | N = 564 | 93/100 | PMID 42163822 ↗ |
| Can This Approach Help? Inside the Latest Research on Sustained on/off-treatment disease control with abrocitinib for After 12 weeks of abrocitinib 200 mg, some patients achieved 40 weeks of sustained off-treatment disease control, with assessments demonstrating clear/mild AD, suggesting attainment of disease full symptom relief. The Journal of dermatological treatment • 2026-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42165315 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparative real-world benefits and safety of biosimilar Bmab 1200 versus Bmab 1200 demonstrated clinical biosimilarity to reference ustekinumab through Week 52 even after switching. Expert opinion on biological therapy • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41100115 ↗ |
| Can This Approach Help? Inside the Latest Research on Time to Loss of Response following Withdrawal of Ixekizumab in Patients with A small subset of patients maintained high levels of disease control through Week 60. Acta dermato-venereologica • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35170742 ↗ |
Scars Patient Community & “People Like Me” Threads
Filter Scars community threads and patient logs by age, biological sex, dosage, and treatment duration.